However, a phase I/II trial of siltuximab (anti-IL-6 monoclonal antibody) in ovarian cancer patients demonstrated a lack of clinical efficacy [48], arguing that IL-6 inhibition could eliminate IL-6 sensitive clones leading to the development of resistant clones whose growth is triggered by other pathways such as the gp130 family [49]. This evidence concerns the gene IL6 and ovarian cancer.